Lessons from a pilot study of transfer factor in chronic fatigue syndrome

Abstract

Transfer Factor (TF) was used in a placebo controlled pilot study of 20 patients with chronic fatigue syndrome (CFS). Efficacy of the treatment was evaluated by clinical monitoring and testing for antibodies to Epstein-Barr virus (EBV) and human herpes virus-6 (HHV-6). Of the 20 patients in the placebo-controlled trial, improvement was observed in 12 patients, generally within 3-6 weeks of beginning treatment. Herpes virus serology seldom correlated with clinical response. This study provided experience with oral TF, useful in designing a larger placebo-controlled clinical trial.

This is a preview of subscription content, access via your institution.

Abbreviations

CFS:

chronic fatigue syndrome

CMV:

cytomegalovirus

EBV:

Epstein-Barr virus

EBV-EA:

EBV-early antigens

EBV-VCA:

EBV-Viral capsid antigen

HHV-6:

human herpes virus-6

HSV:

Herpes simplex virus

TF:

transfer factor

NTF:

non-specific transfer factor

pt:

patient

References

  1. 1.

    Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG & Komaroff A. International Chronic Fatigue Syndrome Study Group. The Chronic fatigue syndrome: a comprehensive approach to its definition. Ann Int Med 1994; 121: 953–9.

    PubMed  CAS  Google Scholar 

  2. 2.

    Nkrumah F, Pizza G, Viza D, Phillips J, De Vinci C & Levine PH. Regression of progressive lymphadenopathy in a young child with acute cytomegalovirus (CMV) infection following the administration of transfer factor with specific anti-CMV activity. Lymphokine Res 1985; 4: 237–41.

    PubMed  CAS  Google Scholar 

  3. 3.

    Neequaye J, Viza D, Pizza D, Levine PH, De Vinci C, Ablashi DV, Biggar RJ & Nkrumah FK. Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt’s lymphoma. Anticanc R 1990; 10: 1183–1187.

    CAS  Google Scholar 

  4. 4.

    Viza D, Vich JM, Phillips J & Rosenfeld F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphokine Res 1985; 4: 27–30.

    PubMed  CAS  Google Scholar 

  5. 5.

    Rosenfeld F, Viza D, Phillips J, Vich JM, Binet O & Aron-Brunetière R. Traitement des infections herpétiques par le facteur de transfert. Presse Méd 1984; 13: 537–540.

    PubMed  CAS  Google Scholar 

  6. 6.

    Meduri R, Campos E, Scorolli L, De Vinci C, Pizza G & Viza D. Transfer Factor in recurrent ocular herpes. Biotherapy, this issue.

  7. 7.

    Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola F & Baricordi OR. Orally administered HSV-specific Transfer Factor (TF) prevents genital and/or labial herpes relapses. Biotherapy, this issue.

  8. 8.

    Viza D, Vich JM, Phillips J, Rosenfeld F & Davies DAL. Specific transfer factor protects mice against lethal challenge with herpes simplex virus. Cell Immun 1986; 100: 555–562.

    Article  Google Scholar 

  9. 9.

    Buchwald D, Cheney PR, Peterson DL, Henry B, Wormsley SB, Geiger A, Ablashi DV, Salahuddin SZ, Saxinger C, Biddle R, Kilkinis R, Jolesz FA, Folks T, Balachandran N, Gallo RD & Komaroff AL. A chronic illness characterized by fatigue, neuralgia, and immunologic disorders and active herpesvirus-6 type infection. Ann Int Med 1992; 116: 103–113.

    PubMed  CAS  Google Scholar 

  10. 10.

    Pizza G, Viza D, Ablashi DV, Jerome L, Armstrong G & Levine PH. The possible use of specific transfer factor in the treatment of patients with nasopharyngeal carcinoma. In: Grundman E, Krueger GRF, Ablashi DV eds, Nasopharyngeal Carcinoma. Stuttgart: Gustav Fisher-Verlag Editor, 1981, 301–307.

    Google Scholar 

  11. 11.

    Viza D, Goust JM, Moulias R, Trejdosiewicz LK, Collard A & Mueller-Berat N. ‘In vitro’ production of transfer factor by lymphoblastoid cell lines. Transplan P 1975; VII (suppl. 1): 329–333.

    Google Scholar 

  12. 12.

    Ablashi DV, Levine PH, Kaplan M, DeVinci C, Whitman JE, Pizza G & Viza D. In Vivo Effectiveness of anti HHV-6 transfer factor in two patients with chronic fatigue syndrome (CFS) Biotherapy, this issue.

  13. 13.

    Levine PH: The use of transfer factors in chronic fatigue syndrome: prospects and problems. Biotherapy, this issue.

  14. 14.

    Straus SE, Dale JK, Tobi M, et al. Acyclovir treatment of the chronic fatigue syndrome: lack of efficacy in a placebocontrolled trial. N Eng J Med 1988; 319: 1692–98.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dr. Caterina De Vinci.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

De Vinci, C., Levine, P.H., Pizza, G. et al. Lessons from a pilot study of transfer factor in chronic fatigue syndrome. Biotherapy 9, 87–90 (1996). https://doi.org/10.1007/BF02628663

Download citation

Key words

  • CMV
  • chronic fatigue syndrome
  • EBV
  • herpes viruses
  • HHV-6
  • transfer factor